Roles of natural killer cells in immunity to cancer, and applications to immunotherapy

• Published in: Nature reviews. Immunology Vol. 23; no. 2; pp. 90 - 105
• Main Authors: Wolf, Natalie K, Kissiov, Djem U, Raulet, David H
• Format: Journal Article
• Language: English
• Published: England Nature Publishing Group 01.02.2023
• Subjects: Cancer; Chemokines; Chimeric antigen receptors; Cytotoxicity; Humans; Immune checkpoint inhibitors; Immunity, Innate; Immunotherapy; Inflammation; Killer Cells, Natural; Lymphocytes T; Lymphoid cells; Major histocompatibility complex; Natural killer cells; Neoantigens; Neoplasms - therapy; Peptides; T-Lymphocytes; Tumors
• ISSN: 1474-1733; 1474-1741
• DOI: 10.1038/s41577-022-00732-1

Great strides have been made in recent years towards understanding the roles of natural killer (NK) cells in immunity to tumours and viruses. NK cells are cytotoxic innate lymphoid cells that produce inflammatory cytokines and chemokines. By lysing transformed or infected cells, they limit tumour growth and viral infections. Whereas T cells recognize peptides presented by MHC molecules, NK cells display receptors that recognize stress-induced autologous proteins on cancer cells. At the same time, their functional activity is inhibited by MHC molecules displayed on such cells. The enormous potential of NK cells for immunotherapy for cancer is illustrated by their broad recognition of stressed cells regardless of neoantigen presentation, and enhanced activity against tumours that have lost expression of MHC class I owing to acquired resistance mechanisms. As a result, many efforts are under way to mobilize endogenous NK cells with therapeutics, or to provide populations of ex vivo-expanded NK cells as a cellular therapy, in some cases by equipping the NK cells with chimeric antigen receptors. Here we consider the key features that underlie why NK cells are emerging as important new additions to the cancer therapeutic arsenal.